Higher serum 25-hydroxy vitamin D3 levels at presentation are associated with improved survival from melanoma, but there is no evidence that later prevailing levels are protective

Journal of Clinical Oncology

Volumn 28, Issue 27, 2010, Pages

  Hutchinson, Peter E ^a   Osborne, Joy E ^b   Pringle, James H ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL; VITAMIN RECEPTOR; BIOLOGICAL MARKER; COLECALCIFEROL;

CANCER GROWTH; CANCER INVASION; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MELANOMA; MICROMETASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SKIN CANCER; SKIN MELANOMA; SUN EXPOSURE; VITAMIN BLOOD LEVEL; BLOOD; DIET SUPPLEMENTATION; EVIDENCE BASED MEDICINE; MORTALITY; NOTE; PATHOLOGY; RISK ASSESSMENT; SKIN TUMOR; SURVIVAL RATE; TIME; TREATMENT OUTCOME; UPREGULATION;

BIOLOGICAL MARKERS; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; HUMANS; MELANOMA; NEOPLASM STAGING; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 77957952443     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.6095     Document Type: Letter

References (12)

1. Newton-Bishop JA, Beswick S, Randerson-Moor J, et al: Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 27:5439-5444, 2009
2. Hutchinson PE, Osborne JE, Lear JT, et al: Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 6:498-504, 2000 (Pubitemid 30111470)
3. Halsall JA, Osborne JE, Potter L, et al: A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibility and prognosis in malignant melanoma. Br J Cancer 91:765-770, 2004 (Pubitemid 39141638)
4. Garland CF, Comstock GW, Garland FC, et al: Serum 25-hydroxyvitamin D and colon cancer: Eight-year prospective study. Lancet 2:1176-1178, 1989
5. Hanchette CL, Schwartz GG: Geographic patterns of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation. Cancer 70:2861-2869, 1992
6. John EM, Schwartz GG, Dreon DM, et al: Vitamin D and breast cancer risk: The NHANES I Epidemiologic follow-up study, 1971-1975 to 1992 - National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 8:399-406, 1999
7. Giovannucci E, Liu Y, Rimm EB, et al: Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98:451-459, 2006
8. Adorini L, Penna G, Giarratana N, et al: Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J Steroid Biochem Mol Biol 89-90:437-441, 2004 (Pubitemid 38844326)
9. Kaneno R, Duarte AJ, Borelli A: Natural killer activity in the experimental privational rickets. Immunol Lett 81:183-189, 2002 (Pubitemid 34310223)
10. Matusiak D, Murillo G, Carroll RE, et al: Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidemiol Biomarkers Prev 14:2370-2376, 2005 (Pubitemid 41437839)
11. Evans SR, Houghton AM, Schumaker L, et al: Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J Surg Res 61:127-133, 1996 (Pubitemid 26066040)
12. Reichrath J, Rech M, Moeini M, et al: In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells. Cancer Biol Ther 6:48-55, 2007